161 related articles for article (PubMed ID: 34064441)
1. TET2 Inhibits
Shen Y; Liu L; Wang M; Xu B; Lyu R; Shi YG; Tan L
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34064441
[TBL] [Abstract][Full Text] [Related]
2. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.
Elashi AA; Sasidharan Nair V; Taha RZ; Shaath H; Elkord E
Oncoimmunology; 2019; 8(2):e1542918. PubMed ID: 30713804
[TBL] [Abstract][Full Text] [Related]
4. Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma.
Peng D; He A; He S; Ge G; Wang S; Ci W; Li X; Xia D; Zhou L
Int J Biol Sci; 2022; 18(3):995-1007. PubMed ID: 35173532
[TBL] [Abstract][Full Text] [Related]
5. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.
Noman MZ; Janji B; Abdou A; Hasmim M; Terry S; Tan TZ; Mami-Chouaib F; Thiery JP; Chouaib S
Oncoimmunology; 2017; 6(1):e1263412. PubMed ID: 28197390
[TBL] [Abstract][Full Text] [Related]
6. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
7. Role of TET Dioxygenases and DNA Hydroxymethylation in Bisphenols-Stimulated Proliferation of Breast Cancer Cells.
Li Z; Lyu C; Ren Y; Wang H
Environ Health Perspect; 2020 Feb; 128(2):27008. PubMed ID: 32105160
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
9. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Sasidharan Nair V; Toor SM; Ali BR; Elkord E
Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
[TBL] [Abstract][Full Text] [Related]
11. TET2 inhibits tumorigenesis of breast cancer cells by regulating caspase-4.
Zhu X; Li S
Sci Rep; 2018 Nov; 8(1):16167. PubMed ID: 30385776
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
13. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications.
Darvin P; Sasidharan Nair V; Elkord E
J Oncol; 2019; 2019():3958908. PubMed ID: 30915120
[TBL] [Abstract][Full Text] [Related]
15. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
16. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
[TBL] [Abstract][Full Text] [Related]
17. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
Yang M; Li Z; Tao J; Hu H; Li Z; Zhang Z; Cheng F; Sun Y; Zhang Y; Yang J; Wei H; Wu Z
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1101-1113. PubMed ID: 33471184
[TBL] [Abstract][Full Text] [Related]
19. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Chen JY; Luo CW; Lai YS; Wu CC; Hung WC
Oncogenesis; 2017 Aug; 6(8):e369. PubMed ID: 28785073
[TBL] [Abstract][Full Text] [Related]
20. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
